Relmada Therapeutics, Inc.
RLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$79,979 | -$98,792 | -$157,044 | -$125,752 |
| Dep. & Amort. | $0 | $0 | $0 | $1 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $30,189 | $0 | $44,195 | $40,494 |
| Change in WC | -$1,584 | $3,080 | $10,593 | -$7,865 |
| Other Non-Cash | -$382 | $44,052 | -$1,546 | $1,247 |
| Operating Cash Flow | -$51,756 | -$51,659 | -$103,802 | -$91,873 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $0 | $0 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$12,080 | -$90,464 | -$47,294 | -$222,982 |
| Inv. Sales/Matur. | $63,641 | $140,917 | $67,027 | $168,864 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $51,562 | $50,453 | $19,734 | -$54,118 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $247 | $0 | $42,729 | $185,311 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$287 | -$98 | $2,292 | $2,628 |
| Financing Cash Flow | -$40 | -$98 | $45,020 | $187,939 |
| Forex Effect | $0 | -$0 | $0 | $0 |
| Net Chg. in Cash | -$235 | -$1,304 | -$39,048 | $41,948 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $4,092 | $5,396 | $44,443 | $2,495 |
| End Cash | $3,857 | $4,092 | $5,396 | $44,443 |
| Free Cash Flow | -$51,756 | -$51,659 | -$103,802 | -$91,873 |